AXE COMPUTE INC

AGPUNASDAQ

🏆 #3423 by market capEarnings Aug 17US Equity

$7.79▼ $0.58 (−7.48%)

Market closed · at close

1h—

24h▼ 7.5%

7d▼ 15.2%

14d▲ 10.5%

30d▲ 11.6%

1y▼ 29.0%

🏦Market Cap

$90M

Small Cap

📈Revenue Growth (YoY)

-96.3%

Declining

📊Gross Margin

31.8%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

1903.2x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $7.69 – $7.82
52-Week Range: $1.03 – $32.10
Volume: $3.37B
Avg Volume: $4.43B
Shares Outstanding: 11.5M
Next Earnings: Sep 16, 2026

Fundamentals Snapshot

Annual Revenue: $125,284
Last Q Revenue: $35,311
P/E Ratio: —
P/S Ratio: 1903.2x
EPS (TTM): $-119.69
Dividend Yield: —

Why Investors Own AGPU

✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$125,284▲ +18.9% YoY

Gross Margin (TTM)

66.7%▼ −0.3% YoY

Operating Income (TTM)

$38,086▲ +18.9% YoY

Free Cash Flow (TTM)

$12,027▲ +18.9% YoY

About AXE COMPUTE INC

Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.

🦦